BRAF and triple-negative breast carcinoma: As a point of reference colorectal cell lines with BRAF mutations, which would be regarded as sensitive in general have IC50s for refametinib ranging from 50nM to >1000 nM [23, 24], whilst the triple negative breast cancer cell line MDAMB231 has an IC50 of less than 100nM [25].